These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 2893652

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of repeated ipsapirone treatment on hippocampal excitatory synaptic transmission in the freely behaving rat: role of 5-HT1A receptors and relationship to anxiolytic effect.
    Xu L, Anwyl R, De Vry J, Rowan MJ.
    Eur J Pharmacol; 1997 Mar 26; 323(1):59-68. PubMed ID: 9105877
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
    Meller E, Goldstein M, Bohmaker K.
    Mol Pharmacol; 1990 Feb 26; 37(2):231-7. PubMed ID: 1968223
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies.
    Schechter LE, Bolaños FJ, Gozlan H, Lanfumey L, Haj-Dahmane S, Laporte AM, Fattaccini CM, Hamon M.
    J Pharmacol Exp Ther; 1990 Dec 26; 255(3):1335-47. PubMed ID: 1702155
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
    Koek W, Patoiseau JF, Assié MB, Cosi C, Kleven MS, Dupont-Passelaigue E, Carilla-Durand E, Palmier C, Valentin JP, John G, Pauwels PJ, Tarayre JP, Colpaert FC.
    J Pharmacol Exp Ther; 1998 Oct 26; 287(1):266-83. PubMed ID: 9765347
    [Abstract] [Full Text] [Related]

  • 16. Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects.
    Berlin I, Warot D, Legout V, Guillemant S, Schöllnhammer G, Puech AJ.
    Clin Pharmacol Ther; 1998 Apr 26; 63(4):428-36. PubMed ID: 9585797
    [Abstract] [Full Text] [Related]

  • 17. Effect of acute and chronic treatment of rats with the putative anxiolytic drug ipsapirone on the turnover of monoamine transmitters in various brain regions. A comparison with the 5-HT1A agonist 8-OH-DPAT.
    Gołembiowska K.
    Pol J Pharmacol Pharm; 1992 Apr 26; 44(1):15-24. PubMed ID: 1359515
    [Abstract] [Full Text] [Related]

  • 18. Evidence for the involvement of the 5-HT1A receptor in the anxiolytic action of indorenate and ipsapirone.
    Fernández-Guasti A, López-Rubalcava C.
    Psychopharmacology (Berl); 1990 Apr 26; 101(3):354-8. PubMed ID: 1972996
    [Abstract] [Full Text] [Related]

  • 19. Comparison of neuroendocrine and behavioral effects of ipsapirone, a 5-HT1A agonist, in three stress paradigms: immobilization, forced swim and conditioned fear.
    Rittenhouse PA, Bakkum EA, O'Connor PA, Carnes M, Bethea CL, van de Kar LD.
    Brain Res; 1992 May 15; 580(1-2):205-14. PubMed ID: 1354556
    [Abstract] [Full Text] [Related]

  • 20. Cerebral pharmacokinetics of ipsapirone in rats after different routes of administration.
    Nocon H, Daniel W, Danek L, Melzacka M.
    J Pharm Pharmacol; 1990 Sep 15; 42(9):642-5. PubMed ID: 1981903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.